ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO1073

Depressive Symptoms in a National CKD Clinical Cohort

Session Information

Category: CKD (Non-Dialysis)

  • 2301 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention

Authors

  • Wrone, Elizabeth M., West Coast Kidney Institute, Concord, California, United States
  • Stedman, Margaret R., Stanford University School of Medicine, Stanford, California, United States
  • Parvathinathan, Gomathy, Stanford University School of Medicine, Stanford, California, United States
  • Kwon, Katherine Westin, Panoramic Health, Tempe, Arizona, United States
  • Mooney, Ann, Panoramic Health, Tempe, Arizona, United States
  • Eckhardt, Douglas, Panoramic Health, Tempe, Arizona, United States
  • Marcus, Roy G., Panoramic Health, Tempe, Arizona, United States
  • Chertow, Glenn M., Stanford University School of Medicine, Stanford, California, United States
  • Brady, Brian, Stanford University School of Medicine, Stanford, California, United States
Background

Depressive symptoms are well described among patients with end-stage kidney disease (ESKD). However, much less is known about the presence and severity of depressive symptoms among patients with non-dialysis-requiring CKD.

Methods

We identified 18,889 patients across 19 states from 25 nephrology practices affiliated with Panoramic Health. We selected patients who completed depression screening with the Patient Health Questionnaire-9 (PHQ-9) the majority of whom were participants in the Comprehensive Kidney Care Contracting (CKCC) program of the US Centers of Medicare and Medicaid Services (CMS). This cross-sectional analysis examines the association between PHQ-9 score (outcome) and CKD stage (primary exposure) and includes clinical data to explore bias and heterogeneity. The CKD-EPI 2021 equation was used to calculate eGFR.

Results

The Table shows demographics, CKD and PHQ-9 categories. Depressive symptoms considered mild (PHQ-9 score 5-9), moderate (10-14), moderate to severe (15-19) and severe (20-27) were observed in 16.7%, 5.8%, 2.3%, and 0.8% of patients, respectively. The Figure shows the distribution of PHQ-9 score by CKD stages G1/2, G3a, G3b, G4, G5 (not receiving dialysis), and G5d (ESKD).

Conclusion

Depressive symptoms are relatively common in patients with non-dialysis-requiring CKD. We find the prevalence and severity of symptoms directly correlate with CKD stage and warrant further study.

Funding

  • Clinical Revenue Support

Digital Object Identifier (DOI)